# NCT01970865 (NCT01970865)

> A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01970865
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
- Interventions: PF-06463922; Crizotinib
- Enrollment: 364
- Primary outcome: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1
- Primary outcome: Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)

## Indexed commentary on NCT01970865 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01970865